Organic Process Research & Development 2009, 13, 102–105
Synthesis of Tetracyclic Heterocompounds as Selective Estrogen Receptor
Modulators. Part 3. Development of an Acid-Catalyzed Racemization Process for
(
S)-2,8-(Dimethoxy)-5-{4-[2-(1-piperidinyl)ethoxy]-
phenyl}-11,12-dihydro-5H-6,13-dioxabenzo[3,4]cyclohepta[1,2-a]naphthalene
,
†
†
§
‡
§
§
§
Xun Li,* Ronald K. Russell, Andr a´ s Horv a´ th, Nareshkumar Jain, Dominique Depr e´ , Dominic Ormerod, Wim Aelterman,
‡
and Zhihua Sui
Johnson & Johnson Pharmaceutical Research and DeVelopment, L.L.C., U.S. East Coast Research and Early DeVelopment,
1
000 Route 202, Raritan, New Jersey 08869, U.S.A., and Johnson and Johnson Pharmaceutical Research and DeVelopment,
A DiVision of Janssen Pharmaceutica, Turnhoutseweg 30, B-2340 Beerse, Belgium
Abstract:
although it was known that the very similar (R)-3-(4-hydrox-
A novel and economical process was developed for recycling the
undesired enantiomer, (S)-2,8-dimethoxy-5-{4-[2-(1-piperidinyl)-
ethoxy]phenyl}-11,12-dihydro-5H-6,13-dioxabenzo[3,4]cyclohep-
ta[1,2-a]naphthalene (1b) obtained from chiral chromatographic
separation, by refluxing 1b with HCl (4.0 equiv) in EtOH for 76 h,
yphenyl)-4-methyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2H-
chromen-7-ol (2a, Scheme 2), a 2,3,4,7-substituted coumarin
derivative, could be easily converted to a racemic mixture in
92% yield, after treatment with 5% LiOH in DMF at 80 °C for
3
4
3 h. Due to the similarity, compound (R)-3a (99.0% ee), the
2,8-dihydroxy analogue of (R)-1a, was first subjected to these
known base-catalyzed conditions (5% LiOH in DMF at 80 °C)
to produce a 63.3% (R)-3a enriched mixture after 60 h. The
rate slowed unacceptably toward the end of the reaction, and
no further optimization was conducted with LiOH-catalyzed
racemization of (R)-3a.
2 4
or with H SO (2.0 equiv) in water for 68 h to afford a near
racemic mixture ((R)-1a/(S)-1b ) 41-42%/49-53%, chiral
HPLC area%) in >96% isolated yield and good chemical
purity (87-95%).
Introduction
When the above LiOH-catalyzed conditions were applied
to pure 2,8-dimethoxy (R)-1a enantiomer (99.8% ee), however,
no product (S)-1b was detected in the reaction mixture as
analyzed by chiral HPLC. In addition, the treatment of (R)-1a
separately with other bases (such as KOH, piperidine, and
The scale-up preparation of 2,5,8-substituted 11,12-dihydro-
5H-6,13-dioxabenzo[3,4]cyclohepta-[1,2-a]naphthalene deriva-
tives as selective estrogen receptor modulators (SERMs) has
been reported recently, where racemate 1 was prepared via an
1
eight-step nonchromatographic linear synthetic process in 17%
overall yield with 99.5% chemical purity (RPHPLC, area %).
Chiral HPLC separation of 1 afforded (R)-enantiomer 1a and
the corresponding (S)-enantiomer 1b (Scheme 1). Furthermore,
the advanced in Vitro and in ViVo biological studies determined
that (R)-1a was the most active compound with the desired
SERM activity, while (S)-1b was the enantiomer with weak
SERM activity. Because attempts for either enantioselective
asymmetric synthesis of (R)-1a or the enantiomeric resolution
4
-(N,N-dimethyl)pyridine) in different refluxing solvents (such
as MeOH, EtOH, and MeCN) also did not result in (S)-1b. It
seemed that a base deprotonation of 2- and/or 8-phenolic
hydroxyl group (calculated pK s of 2-OH and 8-OH ) 10.19
and 9.88, respectively) of (R)-3a was the driving force for this
base-catalyzed racemization. The enantiomer (R)-1a was unable
to be racemized under investigated basic conditions because of
having 2,8-dimethoxy groups on the molecule.
The unsuccessful racemizations of (R)-1a/(S)-1b under basic
conditions led us to explore other possible chemistries. For
instance, (R)-1a/(S)-1b could possibly be racemized under acid-
a
1
2
of the racemate 1 with chiral acids were unfruitful, the optically
pure (>99% ee) (R)-1a was obtained on kilogram scale by the
chiral chromatographic separation of racemate 1. The conversion
of (S)-1b back to the racemic 1 would help in a higher yield of
5
catalyzed conditions when more than one equivalent of an acid
was used, due to the presence of the piperidine ring on the side
(R)-1a within a short time cycle. Herein, we report an acid-
catalyzed racemization process for recycling (S)-1b.
(
(
3) Gauthier, S.; Caron, B.; Cloutier, J.; Dory, Y. L.; Favre, A.; Larouche,
D.; Mailhot, J.; Ouellet, C.; Schwerdtfeger, A.; Leblanc, G.; Martel,
C.; Simard, J.; Merand, Y.; Belanger, A.; Labrie, C.; Labrie, F. J. Med.
Chem. 1997, 40, 2117.
Results and Discussion
A review of the literature showed no published results on
the racemization of a tetracyclic compound like (R)-1a/(S)-1b,
4) The optically pure (99.0% ee) (R)-enantiomer 3a was obtained from a
preparative chiral HPLC separation of its racemate 3, which was
prepared in-house and described as compound 11 in ref 1a of this
publication.
*
Author for correspondence. Telephone: (908)707-3321. Fax: (908)526-6469.
E-mail: xli6@its.jnj.com.
(5) (a) Jiang, Y. L.; Stivers, J. T. Tetrahedron Lett. 2003, 44, 4051. (b)
Cheng, K.; Liang, G.; Hu, C. Molecules 2008, 13, 938. (c) Zhang, L.-
H.; Gupta, A. K.; Cook, J. M. J. Org. Chem. 1989, 54, 4708.
(6) (a) Stahl, P. H.; Wermuth, C. G., Eds. Handbook of Pharmaceutical
Salts Properties, Selection, and Use; Wiley-VCH: Z u¨ rich, Switzerland,
2002; Vol. 28, p 75. (b) Stahl, P. H.; Wermuth, C. G., Eds. Handbook
of Pharmaceutical Salts Properties, Selection, and Use; Wiley-VCH:
Z u¨ rich, Switzerland, 2002; Vol. 28, pp 9-290. (c) Leuches, M.; Zundel,
G. Can. J. Chem. 1980, 58, 311.
†
High Out Put Synthesis, EC RED, U.S.A.
Medicinal Chemistry Team VI, EC RED, U.S.A.
API Development, Janssen Pharmaceutica, Belgium.
‡
§
(
1) (a) Li, X.; Reuman, M.; Russell, R. K.; Youells, S.; Beish, S.; Hu, Z.;
Branum, S.; Jain, N.; Sui, Z. Org. Process Res. DeV. 2007, 11, 731.
(b) Kanojia, R. M.; Jain, N. F.; Ng, R.; Sui, Z.; Xu, J. WO2003053977,
2
003.
(
2) Unpublished internal communications.
1
02
•
Vol. 13, No. 1, 2009 / Organic Process Research & Development
10.1021/op800237y CCC: $40.75 2009 American Chemical Society
Published on Web 12/31/2008